Boston, USA, September 26, 2024 -- The annual most valuable biotech selection by Endpoints News, "The Endpoints 11 award", was announced. MediLink therapeutics (“MediLink”) was selected as one, and the only one from China, of the E11 2024 award recipients. 

(Source: Endpoints News, https://endpts.com/endpoints-11-winner-medilink-therapeutics-china-startup-helps-power-the-adc-renaissance/)

Endpoints News was founded in 2016, to deliver the best news product in biopharma and become an essential read for industry leaders across the globe. Endpoints News is a member of the Financial Times family. Thanks to an ambitious team of journalists across the US, Europe and Asia, Endpoints News is now read by thousands of innovative biotechs and every top 50 pharmaceutical company in the world. 

MediLink marks the first local biotech from China to win this award. Along with MediLink, this year’s Endpoints 11 awarding list includes rising stars such as Capstan Therapeutics which was founded by the CAR-T pioneer Professor Carl June, Mirador Therapeutics which was founded by previous Prometheus teams with a 400-million-dollar fundraising, etc. In Endpoints’ commentary, MediLink is described as the “Chinese startup helps power the ADC renaissance." Dr. Tony Tongtong Xue and Dr. Steve Chin, CEO and CMO of MediLink, respectively, and the MediLink US team States attended the award ceremony. 

“Many thanks to Endpoints News, who has been a prestigious professional biopharma media, for recognizing us," said Dr. Tony Tongtong Xue, CEO of MediLink. "We are honored to be the first local biotech from Chnia to win the E11 award, as well as the only one out of the US in this year. I would like to thank all MediLink colleagues, researchers and patients who have contributed in the development of MediLink’s projects. Also, I think this reflects the growing recognition of the whole biotech industry in China. We will continue to strive to provide more valuable drugs for global patients.”